Pathophysiology of non-motor signs in Parkinson’s disease: some recent updating with brief presentation
Khaled Radad , Rudolf Moldzio , Christopher Krewenka , Barbara Kranner , Wolf-Dieter Rausch
Exploration of Neuroprotective Therapy ›› 2023, Vol. 3 ›› Issue (1) : 24 -46.
Parkinson’s disease (PD) is a progressive neurodegenerative disorder affecting 1% of the population above sixty years. It is caused by an interaction between genetic and environmental risk factors. Loss of dopaminergic neurons in substantia nigra pars compacta (SNpc) is pathologically characterizing the disease and responsible for the cardinal motor symptoms, most notably, bradykinesia, rest tremors, rigidity, and loss of postural reflexes. Non-motor signs such as olfactory deficits, cognitive impairment, sleep behavior disorders, and gastrointestinal disturbances are reflecting disturbances in the non-dopaminergic system. They precede dopaminergic neuronal degenerations by 5–10 years and are considered the main contributors to patients’ disability, particularly after the successful implementation of levodopa (L-dopa) treatment of motor symptoms. The present general review aimed to briefly update non-motor signs and their underlying pathophysiology in PD.
Parkinson’s disease / non-motor signs / olfactory / depression / sleep disorders / constipation
| [1] |
|
| [2] |
|
| [3] |
|
| [4] |
|
| [5] |
|
| [6] |
|
| [7] |
|
| [8] |
|
| [9] |
|
| [10] |
|
| [11] |
|
| [12] |
|
| [13] |
|
| [14] |
|
| [15] |
|
| [16] |
|
| [17] |
|
| [18] |
|
| [19] |
|
| [20] |
|
| [21] |
|
| [22] |
Marsh L. Depression and Parkinson’s disease: current knowledge. Curr Neurol Neurosci Rep. 2013; 13: 409. |
| [23] |
|
| [24] |
|
| [25] |
Hesse S, Meyer PM, Strecker K, Barthel H, Wegner F, Oehlwein C, |
| [26] |
|
| [27] |
|
| [28] |
|
| [29] |
Yamamoto M. Depression in Parkinson’s disease: its prevalence, diagnosis, and neurochemical background. J Neurol. 2001; 248: III5-11. |
| [30] |
Lieberman A. Depression in Parkinson’s disease - a review. Acta Neurol Scand. 2006; 113: 1-8. |
| [31] |
|
| [32] |
|
| [33] |
|
| [34] |
|
| [35] |
|
| [36] |
|
| [37] |
|
| [38] |
Arabia G, |
| [39] |
|
| [40] |
Mössner R, Henneberg A, Schmitt A, |
| [41] |
|
| [42] |
Cummings JL. Behavioral complications of drug treatment of Parkinson’s disease. J Am Geriatr Soc. 1991; 39: 708-16. |
| [43] |
Santamaria J, Tolosa E. Clinical subtypes of Parkinson’s disease and depression. In: Huber SJ, Cummings JL, editors. Parkinson’s disease: neurobehavioral aspects. New York: Oxford University Press; 1992. pp. 217-8. |
| [44] |
|
| [45] |
|
| [46] |
Choi C, |
| [47] |
|
| [48] |
|
| [49] |
|
| [50] |
|
| [51] |
|
| [52] |
|
| [53] |
|
| [54] |
|
| [55] |
|
| [56] |
Henderson R, Kurlan R, Kersun JM, Como P. Preliminary examination of the comorbidity of anxiety and depression in Parkinson’s disease. J Neuropsychiatry Clin Neurosci. 1992; 4: 257-64. |
| [57] |
|
| [58] |
|
| [59] |
|
| [60] |
|
| [61] |
|
| [62] |
Coe S, Franssen M, Collett J, Boyle D, Meaney A, Chantry R, |
| [63] |
|
| [64] |
|
| [65] |
|
| [66] |
Berg D, Lang AE, Postuma RB, Maetzler W, Deuschl G, Gasser T, |
| [67] |
|
| [68] |
|
| [69] |
|
| [70] |
|
| [71] |
|
| [72] |
|
| [73] |
|
| [74] |
|
| [75] |
|
| [76] |
|
| [77] |
|
| [78] |
Parkinson Study Group. Pramipexole in levodopa-treated Parkinson disease patients of African, Asian, and Hispanic heritage. Clin Neuropharmacol. 2007; 30: 72-85. |
| [79] |
|
| [80] |
|
| [81] |
Zhu K, van Hilten JJ, |
| [82] |
|
| [83] |
|
| [84] |
|
| [85] |
|
| [86] |
|
| [87] |
|
| [88] |
|
| [89] |
|
| [90] |
|
| [91] |
Fénelon G, Soulas T, Cleret de Langavant L, Trinkler I, Bachoud-Lévi AC. Feeling of presence in Parkinson’s disease. J Neurol Neurosurg Psychiatry. 2011; 82: 1219-24. |
| [92] |
|
| [93] |
|
| [94] |
Chang A, Fox SH. Psychosis in Parkinson’s disease: epidemiology, pathophysiology, and management. Drugs. 2016; 76: 1093-118. Erratum in: Drugs. 2016; 76:1319. |
| [95] |
|
| [96] |
|
| [97] |
|
| [98] |
|
| [99] |
|
| [100] |
|
| [101] |
Stebbins GT, Goetz CG, Carrillo MC, Bangen KJ, Turner DA, Glover GH, |
| [102] |
Okada K, Suyama N, Oguro H, Yamaguchi S, |
| [103] |
|
| [104] |
|
| [105] |
|
| [106] |
|
| [107] |
|
| [108] |
|
| [109] |
|
| [110] |
|
| [111] |
|
| [112] |
|
| [113] |
|
| [114] |
|
| [115] |
|
| [116] |
|
| [117] |
|
| [118] |
Schifitto G, |
| [119] |
|
| [120] |
|
| [121] |
|
| [122] |
|
| [123] |
|
| [124] |
|
| [125] |
|
| [126] |
|
| [127] |
|
| [128] |
|
| [129] |
|
| [130] |
|
| [131] |
|
| [132] |
|
| [133] |
|
| [134] |
|
| [135] |
|
| [136] |
|
| [137] |
|
| [138] |
|
| [139] |
|
| [140] |
|
| [141] |
|
| [142] |
|
| [143] |
|
| [144] |
|
| [145] |
|
| [146] |
Lindqvist D, Hall S, Surova Y, Nielsen HM, Janelidze S, Brundin L, |
| [147] |
|
| [148] |
|
| [149] |
|
| [150] |
|
| [151] |
|
| [152] |
|
| [153] |
|
| [154] |
|
| [155] |
|
| [156] |
Barbeau A. L-Dopa therapy in Parkinson’s disease: a critical review of nine years’ experience. Can Med Assoc J. 1969; 101: 59-68. |
| [157] |
|
| [158] |
|
| [159] |
|
| [160] |
|
| [161] |
|
| [162] |
|
| [163] |
|
| [164] |
|
| [165] |
|
| [166] |
|
| [167] |
Bronner G, Royter V, Korczyn AD, |
| [168] |
|
| [169] |
|
| [170] |
|
| [171] |
|
| [172] |
Bronner G, Hassin-Baer S, |
| [173] |
|
| [174] |
|
| [175] |
|
| [176] |
|
| [177] |
|
| [178] |
|
| [179] |
|
| [180] |
|
| [181] |
|
| [182] |
|
| [183] |
|
| [184] |
|
| [185] |
|
| [186] |
|
| [187] |
|
| [188] |
|
| [189] |
|
| [190] |
|
| [191] |
|
| [192] |
|
| [193] |
|
| [194] |
|
| [195] |
|
| [196] |
|
| [197] |
|
| [198] |
|
| [199] |
|
| [200] |
|
| [201] |
|
| [202] |
|
| [203] |
|
| [204] |
|
| [205] |
|
| [206] |
|
| [207] |
|
| [208] |
|
| [209] |
|
| [210] |
Defazio G, Antonini A, Tinazzi M, |
/
| 〈 |
|
〉 |